immunity resistance
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: group A - renal failure, haemodialysis group B - renal failure, peritoneal dialysis group C - renal failure, no dialysis
Exclusion criteria
Exclusion criteria: group D - renal failure and/or immunocompromising condition or immunosuppressive medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To identify the possible differences (intrapersonal variability) in the proliferative function of: - T-lymphocytes generally (using the phytohemaglutinine tube) - TB-specific lymphocytes (using the Quantiferon-GIT test) - CMV-specific lymphocytes (using the Quantiferon-CMV test) - HB-specific lymphocytes (using the Quantiferon-HB) between the blood samples which were drawn before, during and after the same hemodialysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. differences in the proportion of patients with indeterminate test result in the positive controle tube (phytohaemaglutinine) in the haemodialysis, PD, non-haemodialysis renal failure and control groups 2. differences in the proportion of patients with positive Quantiferon-CMV test in the hemodialysis, PD, non-HD renal failure and control groups 3. differences in the proportion of patients with positive Quantiferon-HB test in the hemodialysis, PD, non-HD renal failure and control groups 4. differences in the proliferative capacity measured as the amount of produced IFN-γ in the positive controle tube between the group of patients with hemodialysis, PD, non-HD renal failure and control group | — |
Countries
Netherlands
Outcome results
None listed